Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)
BACKGROUND: Monoclonal antibodies represent the fastest growing sector of pharmaceutical biotechnology and a number of antibody-based biopharmaceuticals have been approved for cancer treatment. However, in many cases the antibodies used for the treatment of tumors offer only a modest survival benefi...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Istituto Superiore di Sanità
2013-06-01
|
| Series: | Annali dell'Istituto Superiore di Sanità |
| Subjects: | |
| Online Access: | http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0021-25712013000200012&lng=en&tlng=en |